GleamWall
中文EN

KYTX Kyverna Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1994702 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY2.0%
TTM EPS YoY26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-110.7%
ROA-83.8%
ROIC (approx.)-105.6%
Asset turnover—

Leverage & solvency

Liabilities / assets29.7%
Debt / equity0.19x
Current ratio7.01x
Interest coverage-64.90x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$27.02M$24.79M$30.07M$30.01M$30.46M$35.82M$37.43M$33.48M
SG&A expense$15.88M$14.77M$11.29M$9.27M$8.27M$8.59M$9.97M$7.56M
Operating income-$42.90M-$39.56M-$41.37M-$39.28M-$38.73M-$44.41M-$47.41M-$41.04M
Interest expense$728,000$674,000$667,000$444,000$7,000$14,000$25,000$27,000
Net income-$41.94M-$38.32M-$39.73M-$37.80M-$36.79M-$42.08M-$44.63M-$37.49M
EBITDA-$42.80M-$39.26M-$41.02M-$38.91M-$38.43M-$44.11M-$46.91M-$40.48M
EPS (basic)-0.68-0.63-0.66—-0.85-0.97-1.03—
EPS (diluted)-0.68-0.63-0.66—-0.85-0.97-1.03—
Weighted avg. shares (diluted)61.96M60.90M60.43M—43.42M43.23M43.22M—
Balance sheet
Cash & equivalents$31.82M$31.81M$32.19M$124.09M$34.16M$53.44M$56.87M$96.62M
Short-term investments$138.75M$167.62M$204.25M$155.16M$136.97M$158.24M$185.78M$189.36M
Current assets$176.26M$206.54M$241.73M$282.95M$174.93M$214.33M$247.65M$290.60M
PP&E, net$1.36M$1.33M$1.34M$1.55M$1.79M$2.16M$2.44M$3.35M
Total assets$189.44M$219.82M$257.02M$293.83M$187.16M$226.51M$260.65M$304.64M
Current liabilities$25.14M$22.80M$29.67M$36.49M$33.87M$39.79M$33.29M$33.76M
Long-term debt$24.96M$24.88M—$24.74M————
Total debt$24.96M$24.88M—$24.74M————
Total liabilities$56.28M$54.27M$61.44M$61.55M$35.21M$42.13M$36.65M$38.06M
Shareholders' equity$133.15M$165.55M$195.58M$232.28M$151.95M$184.38M$224.01M$266.59M
Net debt-$6.86M-$6.92M—-$99.35M————
Shares outstanding62.54M61.57M60.53M60.39M43.79M43.24M43.22M43.21M
Cash flow statement
Operating cash flow-$35.37M-$40.31M-$41.60M-$33.53M-$43.32M-$31.95M-$44.91M-$37.06M
Capital expenditure$174,000——-$1,000$2,000$4,000$0$532,000
Free cash flow-$35.54M——-$33.53M-$43.32M-$31.95M-$44.91M-$37.59M
Investing cash flow$28.52M$36.13M-$50.20M-$17.29M$22.56M$29.17M$5.58M$29.22M
Financing cash flow$6.86M$3.79M-$101,000$140.74M$1.49M-$649,000-$414,000-$215,000
Depreciation & amortization$100,000$300,000$351,000$368,000$300,000$300,000$501,000$563,000
Stock-based compensation$3.62M$3.51M$3.17M$2.70M$2.70M$2.52M$2.16M$1.38M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.